Patients and Methods
Patients were recruited from inpatients admitted to Osaka University Hospital for treating type 2 diabetes from 2009 to 2011. To eliminate the possibility that some other factors influence serum copper levels, we excluded patients suffering from renal dysfunction, hepatic dysfunction, infection, connective tissue disease, malignancy, or taking hypotensive diuretics. In addition, since serum copper levels tend to be high due to insufficient renal function, we recruited the patients whose age was under 80. A total of 132 Japanese type 2 diabetic subjects (76 men and 56 women, age: 58.5 ± 12.5 years, duration of diabetes: 10.7 ± 8.5 years, hemoglobin A1c (HbA1c): 9.0 ± 1.7 % (Japan Diabetes Society) (mean ± SD)) met the criteria and participated in the study. Fasting blood samples were collected and the following laboratory analyses were performed by SRL (Tokyo, Japan). Serum copper levels were measured using a colorimetric method (normal range: 68-128 mg/dL). Serum ceruloplasmin levels were measured using nephelometry and total daily urinal copper levels were measured without pre-treatment using atomic absorption spectrometry. It is noted here 
Results
Patients' characteristics in this study are shown in Table 1 . First, we evaluated the association between serum copper levels and glycemic control state in patients with type 2 diabetes. As shown in Fig. 1 , there was a positive correlation between serum copper and 32/73/27 Data are given as mean ± SD (range). BMI, body mass index; HbA1c, hemoglobin A1c; GA. glycoalbumin; FPG, fasting plasma glucose; IRI, immunoreactive insulin; CPR, C-peptide immunoreactivity; sBP, systolic blood pressure; dBP, diastolic blood pressure; T-Chol, total cholesterol; LDL-chol, lowdensity lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; Hb, hemoglobin; Cre, creatinine; NDR, non-diabetic retinopathy; SDR, simple diabetic retinopathy, PPDR, pre-proliferative diabetic retinopathy, PDR, proliferative diabetic retinopathy; OHA, oral hypoglycemic agent Serum ceruloplasmin or urinal copper levels were not associated with HbA1c levels (n=53, r= -0.074, p=0.60 and n=103, r=0.031, p=0.757, respectively). In addition, there was no association between serum copper levels and diabetic microangiopathy or kinds of therapy (diet, oral hypoglycemic agent and insulin). Next, after 3-month glycemic control, we evaluated the influence of glycemic control on serum copper levels in 41 patients with type 2 diabetes. It is noted here that these patients were all of patients that we followed up in our hospital for three months (n=41). As HbA1c levels were decreased (from 8.7% to 6.8%, p<0.001), copper levels tended to be decreased (from 105.7 µg/ dL to 101.8 µg/dL, p=0.069).
Discussion
In the present study, we examined the association between serum copper levels and glycemic control and showed that serum copper levels were associated with glycemic control in patients with type 2 diabetes. These results were consistent with a previous paper [14] , but the authors of that study did not examine the possible influence of glycemic control on serum copper levels. In this study, we evaluated the influence of glycemic control on serum copper levels and showed that serum copper levels tended to be decreased as glycemic control was improved. In addition, since there was no association between serum copper levels and diabetic microangiopathy or kinds of therapy, we assume that serum copper level were affected by glycemic control per se. It is known that at a high glucose concentration copper ion is released from copper, zinc-superoxide dismutase [15] , which may explain, at least in part, the mechanism of how serum copper levels are increased under diabetic conditions, although the precise mechanism remains unknown. We have recently reported that the reduction of serum copper levels in type 2 diabetic db/db mice using copper chelating agent leads to the amelioration of glycemic control [7] . Taken together, it is possible that the amelioration of glycemic control leads to the reduction of serum copper levels which further leads to the amelioration of glycemic control. In other words, we assume that there is a kind of vicious cycle; the aggravation of glycemic control increases serum copper levels which further aggravate glycemic control.
In conclusion, it is likely that serum copper levels are associated with glycemic control in patients with type 2 diabetes. It is noted, however, that further study is necessary to demonstrate the precise role of serum copper in the pathogenesis of type 2 diabetes and the mechanism of how glycemic control influences serum copper levels.
